An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

NCT07680257 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2 Positive Solid Tumors

Interventions

BIOLOGICAL: SUV2208A cell injection
BIOLOGICAL: SUV2208A
BIOLOGICAL: SUV2208A

Sponsor

Celest Therapeutics (Shanghai) Co., Ltd.

Collaborators

[object Object]